Synthesis and antiviral activity of 8-aza analogs of chiral [2-(phosphonomethoxy) propyl]guanines. 1995

P Franchetti, and G A Sheikha, and L Cappellacci, and M Grifantini, and A De Montis, and G Piras, and A G Loi, and P La Colla
Dipartimento di Scienze Chimiche, Università di Camerino, Italy.

(R)- And (S)-8-aza-9(-)[2-(phosphonomethoxy)propyl]guanine [(R)-and (S)-8-aza-PMPG] were synthesized and tested in vitro for anti-human immunodeficiency virus (HIV) activity. The synthesis of the above compounds and of (R)-9(-)[2-(phosphonomethoxy)propyl]guanine [(R)-PMPG] was carried out through the alkylation of 8-azaguanine or guanine with (R)- and (S)-2-O(-)[(diisopropylphosphono)methyl]-1-O-(tolylsulfonyl) -1,2-propanediol followed by deprotection of the phosphonic moiety. A different, even more convenient synthesis of (R)-8-aza-PMPG starting from 2-amino-6-chloro-5-nitro-4(3H)-pyrimidinone and (R)(-)[2(-)[(diisopropylphosphono)-methoxy]propyl]amine is also reported. Both (R)-8-aza-PMPG and (R)-PMPG demonstrated anti-HIV activity in the MTT assay with EC50 values of 12 and 4.5 microM, respectively. The corresponding S enantiomers were found to be less potent. When evaluated in combination with AZT, ddI, or DABO 603, (R)-8-aza-PMPG gave additive, additive, and synergistic anti-HIV-1 effects, respectively.

UI MeSH Term Description Entries
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006147 Guanine
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001372 Aza Compounds Organic chemicals where carbon atoms have been replaced by nitrogen atoms. Compounds, Aza
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer

Related Publications

P Franchetti, and G A Sheikha, and L Cappellacci, and M Grifantini, and A De Montis, and G Piras, and A G Loi, and P La Colla
November 2007, Journal of medicinal chemistry,
P Franchetti, and G A Sheikha, and L Cappellacci, and M Grifantini, and A De Montis, and G Piras, and A G Loi, and P La Colla
April 2011, Bioorganic & medicinal chemistry,
P Franchetti, and G A Sheikha, and L Cappellacci, and M Grifantini, and A De Montis, and G Piras, and A G Loi, and P La Colla
November 2012, Antiviral research,
P Franchetti, and G A Sheikha, and L Cappellacci, and M Grifantini, and A De Montis, and G Piras, and A G Loi, and P La Colla
September 1993, Journal of medicinal chemistry,
P Franchetti, and G A Sheikha, and L Cappellacci, and M Grifantini, and A De Montis, and G Piras, and A G Loi, and P La Colla
August 1992, Journal of medicinal chemistry,
P Franchetti, and G A Sheikha, and L Cappellacci, and M Grifantini, and A De Montis, and G Piras, and A G Loi, and P La Colla
December 2006, Journal of medicinal chemistry,
P Franchetti, and G A Sheikha, and L Cappellacci, and M Grifantini, and A De Montis, and G Piras, and A G Loi, and P La Colla
March 2007, Journal of medicinal chemistry,
P Franchetti, and G A Sheikha, and L Cappellacci, and M Grifantini, and A De Montis, and G Piras, and A G Loi, and P La Colla
January 2005, Nucleosides, nucleotides & nucleic acids,
P Franchetti, and G A Sheikha, and L Cappellacci, and M Grifantini, and A De Montis, and G Piras, and A G Loi, and P La Colla
January 2005, Nucleosides, nucleotides & nucleic acids,
P Franchetti, and G A Sheikha, and L Cappellacci, and M Grifantini, and A De Montis, and G Piras, and A G Loi, and P La Colla
April 2002, Journal of medicinal chemistry,
Copied contents to your clipboard!